AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12614309 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 600 mg/day
Number of subjects: 613
Study 12614309 — intervention group
Group type: COMPARATOR
Intervention: Valproate (VPA) 1250 mg/day
Number of subjects: 613
Study 10940544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group attendance and participation
Number of subjects: 411
Study 10940544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group emphasis in treatment
Number of subjects: 411
Study 9044341 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-h haemodialysis sessions
Number of subjects: 38
Study 9044341 — intervention group
Group type: COMPARATOR
Intervention: 4-h haemodialysis sessions
Number of subjects: 38
Study 7817684 — intervention group
Group type: EXPERIMENTAL
Intervention: KH 1060 ointment 0.2 microgram/g
Number of subjects: 70
Study 7817684 — intervention group
Group type: EXPERIMENTAL
Intervention: KH 1060 ointment 1 microgram/g
Number of subjects: 70
Study 7817684 — intervention group
Group type: COMPARATOR
Intervention: KH 1060 ointment 0.04 microgram/g
Number of subjects: 70
Study 7817684 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 70
Study 3294405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium/clavulanate potassium
Number of subjects: 47
Study 3294405 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 47
Study 31837264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 24
Study 31837264 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 24
Study 31837264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29098426 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD) for 8 weeks
Number of subjects: 47
Study 29098426 — intervention group
Group type: COMPARATOR
Intervention: Control diet lacking functional components for 8 weeks
Number of subjects: 47
Study 28132008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg)
Number of subjects: 52
Study 28132008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26383718 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding transcatheter aortic valve replacement (TAVR)
Number of subjects: 489
Study 23333772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 50
Study 23333772 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 50
Study 23333772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 20816031 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (4 types)
Number of subjects: 1197
Study 18639298 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg)
Number of subjects: 3047
Study 18639298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxazosin (4 to 8 mg) and finasteride (5 mg)
Number of subjects: 3047
Study 18639298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3047
Study 17054068 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccine (rHAO) 45 microg
Number of subjects: 27
Study 17054068 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccine (rHAO) 135 microg
Number of subjects: 27
Study 17054068 — intervention group
Group type: COMPARATOR
Intervention: Commercial trivalent influenza vaccine (TIV)
Number of subjects: 27
Study 14749151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 3 microg/kg
Number of subjects: 80
Study 14749151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 6 microg/kg
Number of subjects: 80
Study 14749151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 12 microg/kg
Number of subjects: 80
Study 14749151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10671836 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure
Number of subjects: 52
Study 10671836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied with a force of 30 N
Number of subjects: 52
Study 10671836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in an upward and backward direction with a force of 30 N
Number of subjects: 52
Study 10671836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure at 44 N
Number of subjects: 52
Study 7675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynavision tasks of graded difficulty
Number of subjects: 0
Study 2239779 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (UCS)
Number of subjects: 7
Study 2239779 — intervention group
Group type: EXPERIMENTAL
Intervention: UCS:Dex (3:1 mixture)
Number of subjects: 7
Study 2239779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose (Dex)
Number of subjects: 7
Study 2239779 — intervention group
Group type: COMPARATOR
Intervention: Continuous intragastric glucose infusion (COG)
Number of subjects: 7
Study 7360547 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback concerning an audiovisually taped interview and participation in a didactic session on interviewing skills (Group 1)
Number of subjects: 62
Study 7360547 — intervention group
Group type: COMPARATOR
Intervention: Feedback sessions only (Group 2)
Number of subjects: 62
Study 7360547 — intervention group
Group type: COMPARATOR
Intervention: Neither feedback nor didactic sessions (Group 3)
Number of subjects: 62
Study 30833136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical Sequence Analysis (DSA)
Number of subjects: 10
Study 30833136 — intervention group
Group type: COMPARATOR
Intervention: Usual Psychiatric Assessments (AAU)
Number of subjects: 10
Study 28483270 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (5 consultations by an Advanced Practice Nurse over 6 months)
Number of subjects: 49
Study 28483270 — intervention group
Group type: COMPARATOR
Intervention: Written information (predefined set of leaflets)
Number of subjects: 49
Study 28483270 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 49
Study 28483270 — intervention group
Group type: COMPARATOR
Intervention: Written information
Number of subjects: 49
Study 25566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional strategies employed by staff when notifying patients about treatment allocation.
Number of subjects: 18
Study 25566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for practical, emotional, and specialist psychological support for trial staff.
Number of subjects: 18
Study 25566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional management of patients and colleagues by trial staff.
Number of subjects: 18
Study 25566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of patient withdrawal or non-randomization on staff emotions.
Number of subjects: 18
Study 23416808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.25% bupivacaine 15ml on each side
Number of subjects: 60
Study 23416808 — intervention group
Group type: COMPARATOR
Intervention: No regional block administered (Control)
Number of subjects: 60
Study 21111539 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of smoking
Number of subjects: 2257
Study 21111539 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of urges to smoke
Number of subjects: 2257
Study 19664676 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 40
Study 19664676 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 40
Study 19664676 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 40
Study 17280633 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (1500 mg per day)
Number of subjects: 66
Study 17280633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15127380 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 15127380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing
Number of subjects: 0
Study 15127380 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation prophylaxis
Number of subjects: 0
Study 11240976 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg)
Number of subjects: 16
Study 11240976 — intervention group
Group type: COMPARATOR
Intervention: Mibefradil (100 mg)
Number of subjects: 16
Study 11240976 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 16
Study 11240976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9609505 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) intervention
Number of subjects: 46
Study 8923781 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (66 mg ferrous iron daily)
Number of subjects: 90
Study 8923781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2479227 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone (300 mg daily)
Number of subjects: 81
Study 2479227 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene (30 mg daily)
Number of subjects: 81
Study 1098177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-protein complex (Bicitropeptide, BCP-Compound)
Number of subjects: 60
Study 1098177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31059588 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone
Number of subjects: 1088
Study 31059588 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study 28085541 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient (SP) actor‐based simulation in advance care planning (ACP) facilitator training course
Number of subjects: 67
Study 25527736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (1.4 g/day)
Number of subjects: 50
Study 25527736 — intervention group
Group type: COMPARATOR
Intervention: Control meals (placebo)
Number of subjects: 50
Study 25527736 — intervention group
Group type: COMPARATOR
Intervention: Cocoa extract (1.4 g/day) and Control meals
Number of subjects: 50
Study 23497835 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about behaviour
Number of subjects: 453
Study 23497835 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions
Number of subjects: 453
Study 23497835 — intervention group
Group type: EXPERIMENTAL
Intervention: Past behaviour, trial group allocation, and clinical and demographic factors
Number of subjects: 453
Study 21690465 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular completion of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 and Hospital Anxiety and Depression Scale with feedback to oncologists
Number of subjects: 198
Study 21690465 — intervention group
Group type: COMPARATOR
Intervention: Completion of same questionnaires without feedback
Number of subjects: 198
Study 21690465 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 198
Study 19448051 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative reminiscence
Number of subjects: 56
Study 19448051 — intervention group
Group type: COMPARATOR
Intervention: Attention control (health education)
Number of subjects: 56
Study 19448051 — intervention group
Group type: COMPARATOR
Intervention: True control
Number of subjects: 56
Study 16684940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavior treatment (CBT)
Number of subjects: 65
Study 16684940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific intervention to improve adherence to medical recommendations
Number of subjects: 65
Study 15358979 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 15
Study 15358979 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 15
Study 10659875 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 160 mg/m2 3 times per day plus lamivudine, 4 mg/kg 2 times per day
Number of subjects: 297
Study 10659875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir, 350 mg/m2 2 times per day plus zidovudine and lamivudine
Number of subjects: 297
Study 10659875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir, 350 mg/m2 2 times per day plus stavudine, 4 mg/kg 2 times per day
Number of subjects: 297
Study 10659875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus 2 nucleosides
Number of subjects: 297
Study 10659875 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir plus 1 nucleoside
Number of subjects: 297
Study 9231929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide alone (80 mg kg(‐1) daily) with 52.5 Gy in 20 fractions over 4 weeks
Number of subjects: 30
Study 9231929 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen alone with 50 Gy in 20 fractions over 4 weeks
Number of subjects: 30
Study 9231929 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen and nicotinamide with 50-52.5 Gy in 20 fractions over 4 weeks
Number of subjects: 30
Study 9231929 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 30
Study 8149688 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium intake
Number of subjects: 42
Study 8149688 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (5th day)
Number of subjects: 42
Study 8149688 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (5th day)
Number of subjects: 42
Study 4063284 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 or 6 g) with carbohydrate meal (80 ml Hycal)
Number of subjects: 0
Study 4063284 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 or 6 g) with protein meal (150 g cooked lean minced beef)
Number of subjects: 0
Study 4063284 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 or 6 g) with fat meal (200 ml double cream)
Number of subjects: 0
Study 4063284 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g/l solution in water)
Number of subjects: 0
Study 31353274 — intervention group
Group type: EXPERIMENTAL
Intervention: Credentialing of interventionists based on review of last 25 consecutive cases and self-reported lifetime experience.
Number of subjects: 334
Study 31353274 — intervention group
Group type: EXPERIMENTAL
Intervention: Median self-reported lifetime case experience for those approved.
Number of subjects: 334
Study 31353274 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of cases submitted for review.
Number of subjects: 334
Study 31353274 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of CAS procedures performed per month (case rate).
Number of subjects: 334
Study 29933239 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recovery of continuous background activity (within 24 hours)
Number of subjects: 134
Study 29933239 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appearance of an epileptiform EEG
Number of subjects: 134
Study 27163499 — intervention group
Group type: COMPARATOR
Intervention: Ritobegron (20 mg) alone
Number of subjects: 12
Study 27163499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritobegron (20 mg) with probenecid
Number of subjects: 12
Study 24085290 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequencies (n = 29)
Number of subjects: 102
Study 24085290 — intervention group
Group type: COMPARATOR
Intervention: Conditional probabilities (n = 34)
Number of subjects: 102
Study 24085290 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional probabilities with a tree diagram (n = 35)
Number of subjects: 102
Study 22922564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3.0 g/day
Number of subjects: 24
Study 22922564 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) 0.5‐1.0 g/m(2)/month
Number of subjects: 24
Study 22922564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.0 g twice daily
Number of subjects: 24
Study 22922564 — intervention group
Group type: COMPARATOR
Intervention: Oral azathioprine (AZA) 2 mg/kg/day
Number of subjects: 24
Study 19101495 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 40
Study 19101495 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 40
Study 17202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery (undercutting laminectomy, with transpedicular fusion in 10 patients)
Number of subjects: 94
Study 17202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 94
Study 17202885 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 94
Study 15252741 — intervention group
Group type: EXPERIMENTAL
Intervention: P wave signal averaged ECG after electrical cardioversion
Number of subjects: 49
Study 11517139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 5 microg x kg(‐1)
Number of subjects: 30
Study 11517139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 10 microg x kg(‐1)
Number of subjects: 30
Study 11517139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 15 microg x kg(‐1)
Number of subjects: 30
Study 9779768 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once)
Number of subjects: 500
Study 9779768 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (600 mg twice daily for four doses)
Number of subjects: 500
Study 7932137 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (surgery duration > 40 minutes)
Number of subjects: 40
Study 7932137 — intervention group
Group type: COMPARATOR
Intervention: Group B (surgery duration < 40 minutes)
Number of subjects: 40
Study 2894658 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 120
Study 2894658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7412801 — intervention group
Group type: COMPARATOR
Intervention: Heparin followed by oral anticoagulants
Number of subjects: 40
Study 7412801 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (urokinase or streptokinase followed by heparin and then by oral anticoagulants)
Number of subjects: 40
Study 30649897 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing exercise 'snacks' (3 bouts/day of vigorously ascending a 3‐flight stairwell, 60 steps, 3 days/week for 6 weeks)
Number of subjects: 12
Study 30649897 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 12
Study 27518486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebacoyl dinalbuphine ester (SDE) injection (150 mg/2 mL)
Number of subjects: 221
Study 27518486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 25468629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygoid disjunction
Number of subjects: 38
Study 25468629 — intervention group
Group type: COMPARATOR
Intervention: Third molar socket disjunction
Number of subjects: 38
Study 23411106 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated white blood cell count (WBCc) at admission
Number of subjects: 13678
Study 23411106 — intervention group
Group type: EXPERIMENTAL
Intervention: WBCc
Number of subjects: 13678
Study 22005366 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Dartos pouch technique
Number of subjects: 159
Study 22005366 — intervention group
Group type: COMPARATOR
Intervention: Classic sub-Dartos pouch technique
Number of subjects: 159
Study 19775040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral catheter placement
Number of subjects: 45
Study 19775040 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation-guided femoral catheter placement
Number of subjects: 45
Study 18156032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (fluid diet and either polyethylene glycol or sodium phosphate)
Number of subjects: 1431
Study 18156032 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (normal meal the day before surgery)
Number of subjects: 1431
Study 18156032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 1431
Study 18156032 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation
Number of subjects: 1431
Study 15462154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma + atropine + pralidoxime
Number of subjects: 33
Study 15462154 — intervention group
Group type: COMPARATOR
Intervention: Pralidoxime
Number of subjects: 33
Study 15462154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 33
Study 11906441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11906441 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study 9731794 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 (2 mg/kg per hour) during cardiopulmonary bypass (group F)
Number of subjects: 20
Study 9731794 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients, group C)
Number of subjects: 20
Study 9731794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic myocytes (group 2H)
Number of subjects: 20
Study 9731794 — intervention group
Group type: COMPARATOR
Intervention: Normoxic myocytes (group N)
Number of subjects: 20
Study 9731794 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 addition to hypoxic myocytes
Number of subjects: 20
Study 9731794 — intervention group
Group type: EXPERIMENTAL
Intervention: Coincubation of endothelial cells and myocytes (group 2H)
Number of subjects: 20
Study 9731794 — intervention group
Group type: COMPARATOR
Intervention: Normoxic coincubation (group N)
Number of subjects: 20
Study 9731794 — intervention group
Group type: EXPERIMENTAL
Intervention: Coincubation with anti-interleukin-6 monoclonal antibody
Number of subjects: 20
Study 7800195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (80 mg granular sachet)
Number of subjects: 20
Study 7800195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2897812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol (100-300 mg bid)
Number of subjects: 266
Study 2897812 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80-240 mg bid)
Number of subjects: 266